For investors only
All about the drug candidate arfolitixorin
and related information
The animation explains how arfolitixorin works in cancer cells, describing the mechanism of action.
Arfolitixorin is Isofol’s proprietary drug candidate and is currently being evaluated in a pivotal, global clinical phase III study in patients with advanced colorectal cancer. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
Last updated 11-09-2022